Avatrombopag (Su Kexin) is not reimbursed by medical insurance

Avatrombopag is an oral, small-molecule thrombopoietin receptor agonist. It is the world's first drug approved by the FDA for the treatment of thrombocytopenia associated with chronic liver disease (CLD).

Avatropopag is indicated primarily for adult patients with thrombocytopenia associated with chronic liver disease who are scheduled for elective diagnostic procedures or surgery. Avatrombopag increases platelet production by stimulating the proliferation and differentiation of megakaryocytes, among bone marrow progenitor cells. Avatrombopag significantly reduces the proportion of adult patients with CLD-related thrombocytopenia who require platelet transfusions or require resuscitation for bleeding due to elective diagnostic procedures or surgery.

Overall, avatrombopag, with its innovative mechanism and significant clinical effect, provides a new treatment option for patients with chronic liver disease-related thrombocytopenia, improving patients' quality of life and surgical safety. Please note that any medication should be used as directed by your doctor to ensure safety and effectiveness.

Avatrombopag has been launched in the Chinese market and has been included in the reimbursement scope of medical insurance. There are two versions of avatrombopag on the domestic market: the original research version and the domestic generic version, both of which are 20 mg and 15 tablets. After being reimbursed by medical insurance, the price of the original research version is about 4,000 yuan, while the price of the domestic imitation version is more than 3,000 yuan. However, it is reported that there are related generic versions of avatrombopag for sale in overseas markets, which are also in the specifications of 20 mg and 15 tablets, but the price is extremely low, with the lowest price being only about 300 yuan. For the imitation version packed with 30 pieces, the price is only about 1,000 yuan.